id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-310636-y7n22ykt	Garcia-Beltran, W. F.	COVID-19 neutralizing antibodies predict disease severity and survival	2020-10-20		.txt	text/plain	10879	545	47	A quantitative ELISA that measures IgG, IgM, and IgA antibodies to the receptor binding domain (RBD) of SARS-CoV-2 and a high-throughput neutralization assay using lentiviral vectors pseudotyped with SARS-CoV-2 and WIV1-CoV were developed to assess neutralization potency and cross-neutralizing responses. We determined the sensitivity and specificity of this assay by assessing anti-RBD antibody levels in a cohort of SARS-CoV-2-infected patient serum samples collected between 14 to 42 days after symptom onset ( n = 85) in order to maximize seropositivity for IgG, IgM, and IgA. Anti-RBD IgG, IgM, and IgA levels were measured for each sample by interpolation on to the standard curve and a receiver operating curve (ROC) analysis was used to determined optimal cut-offs that distinguished SARS-CoV-2-infected patients from pre-pandemic controls ( Figure 2C ). However, a principle components analysis (PCA) that included demographic data, pre-existing medical conditions, laboratory data, treatments received, anti-RBD antibody levels and neutralization titers but not clinical outcomes demonstrated clustering of patients by the severity cohorts ( Figure 4A ).	./cache/cord-310636-y7n22ykt.txt	./txt/cord-310636-y7n22ykt.txt